- Home
- CLSD vs CTSO Comparison
CLSD vs CTSO Comparison
Compare CLSD & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSD
- CTSO
- Stock Information
- Founded
- CLSD 2011
- CTSO 1997
- Country
- CLSD United States
- CTSO United States
- Employees
- CLSD N/A
- CTSO N/A
- Industry
- CLSD Biotechnology: Pharmaceutical Preparations
- CTSO Medical/Dental Instruments
- Sector
- CLSD Health Care
- CTSO Health Care
- Exchange
- CLSD Nasdaq
- CTSO Nasdaq
- Market Cap
- CLSD 68.6M
- CTSO 68.2M
- IPO Year
- CLSD 2016
- CTSO N/A
- Fundamental
- Price
- CLSD $0.94
- CTSO $0.87
- Analyst Decision
- CLSD Strong Buy
- CTSO Strong Buy
- Analyst Count
- CLSD 5
- CTSO 3
- Target Price
- CLSD $5.20
- CTSO $4.67
- AVG Volume (30 Days)
- CLSD 103.8K
- CTSO 134.8K
- Earning Date
- CLSD 05-14-2025
- CTSO 05-14-2025
- Dividend Yield
- CLSD N/A
- CTSO N/A
- EPS Growth
- CLSD N/A
- CTSO N/A
- EPS
- CLSD N/A
- CTSO N/A
- Revenue
- CLSD $1,664,000.00
- CTSO $35,594,520.00
- Revenue This Year
- CLSD N/A
- CTSO $18.72
- Revenue Next Year
- CLSD $675.15
- CTSO $19.75
- P/E Ratio
- CLSD N/A
- CTSO N/A
- Revenue Growth
- CLSD N/A
- CTSO 14.51
- 52 Week Low
- CLSD $0.70
- CTSO $0.70
- 52 Week High
- CLSD $1.65
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- CLSD 62.45
- CTSO 33.95
- Support Level
- CLSD $0.81
- CTSO $0.87
- Resistance Level
- CLSD $0.90
- CTSO $1.16
- Average True Range (ATR)
- CLSD 0.05
- CTSO 0.05
- MACD
- CLSD 0.01
- CTSO -0.02
- Stochastic Oscillator
- CLSD 99.85
- CTSO 0.00
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.